SIRT6 and neoplasm: A study has reported that inhibition of SIRT6/NF-κB by icariin can alter redox status and enhance anti-tumor immunity and thus contain the growth of triple-negative breast cancer (Song et al., 2020), indicating that the immune reprogramming strategy could be performed through redox intervention.